| dc.creator |
ZORLU, YUNUS |
|
| dc.creator |
AKKOÇ, Senem |
|
| dc.creator |
TÜZÜN, BURAK |
|
| dc.creator |
Tapera, Michael |
|
| dc.creator |
Kekecmuhammed, Huseyin |
|
| dc.creator |
SARIPINAR, EMİN |
|
| dc.date |
2022-07-01T00:00:00Z |
|
| dc.date.accessioned |
2023-01-09T12:01:06Z |
|
| dc.date.available |
2023-01-09T12:01:06Z |
|
| dc.identifier |
2d3174fd-042c-4504-af51-15e9bea8a19f |
|
| dc.identifier |
10.1002/slct.202201502 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/2d3174fd-042c-4504-af51-15e9bea8a19f/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/97702 |
|
| dc.description |
(A new 4-oxothiazolidin-2-ylidene derivative bearing hydrazone moiety was synthesized via Michael addition between the reaction of 4-(4-nitrophenyl)-3-thiosemicarbazide and dimethyl acetylenedicarboxylate (DMAD). The structure of synthesized compound was elucidated using various spectral techniques such as FTIR, UV-spec, H-1 NMR and C-13 NMR. The structure of the related compound was confirmed by single-crystal X-ray analysis. Antiproliferative activity of the synthesized compound was evaluated in two human cancer cell lines, HepG2 (liver hepatocellular carcinoma cell line) and DLD-1 (human colon cancer cell line). In addition, molecular docking of synthesized compound was investigated to give an insight of its activity against Epidermal Growth Factor Receptor tyrosine kinase domain proteins (EGFR) (lung cancer) (PDB ID: 1 M17), deleted in Liver Cancer 2 proteins (DLC2) (liver cancer) (PDB ID: 2H80), and MLK4 kinase proteins (colon cancer) (PDB ID: 4UYA) were investigated. Furthermore, the ability of the molecule to be a drug was examined by ADME/T analysis.) |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Synthesis, Molecular Docking and Antiproliferative Activity Studies of a Thiazole-Based Compound Linked to Hydrazone Moiety |
|
| dc.type |
info:eu-repo/semantics/article |
|